146 related articles for article (PubMed ID: 19498431)
1. Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
Schiff D; Purow BW
Nat Rev Neurol; 2009 Jun; 5(6):303-4. PubMed ID: 19498431
[TBL] [Abstract][Full Text] [Related]
2. [IDH1/2 mutations in gliomas].
Nobusawa S; Yokoo H
Brain Nerve; 2011 Dec; 63(12):1378-86. PubMed ID: 22147457
[TBL] [Abstract][Full Text] [Related]
3. Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas.
Yu L; Qi ST; Li ZY
Chin Med J (Engl); 2010 Dec; 123(24):3697-705. PubMed ID: 22166653
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase 1 and 2 mutations in gliomas.
Megova M; Drabek J; Koudelakova V; Trojanec R; Kalita O; Hajduch M
J Neurosci Res; 2014 Dec; 92(12):1611-20. PubMed ID: 25078896
[TBL] [Abstract][Full Text] [Related]
5. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S; Hirose Y
Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
[TBL] [Abstract][Full Text] [Related]
6. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
Weller M; Wick W; von Deimling A
Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Hodges TR; Choi BD; Bigner DD; Yan H; Sampson JH
J Neurosurg; 2013 Jun; 118(6):1176-80. PubMed ID: 23581583
[TBL] [Abstract][Full Text] [Related]
8. Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
Singh A; Gurav M; Dhanavade S; Shetty O; Epari S
Neuropathology; 2017 Dec; 37(6):582-585. PubMed ID: 28782849
[TBL] [Abstract][Full Text] [Related]
9. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
[TBL] [Abstract][Full Text] [Related]
10. IDH mutations in human glioma.
Kim W; Liau LM
Neurosurg Clin N Am; 2012 Jul; 23(3):471-80. PubMed ID: 22748659
[TBL] [Abstract][Full Text] [Related]
11. New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status.
Shibahara I; Sonoda Y; Kanamori M; Saito R; Kumabe T; Tominaga T
Brain Tumor Pathol; 2011 Jul; 28(3):203-8. PubMed ID: 21735252
[TBL] [Abstract][Full Text] [Related]
12. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
13. Glioma-derived mutations in IDH: from mechanism to potential therapy.
Fu Y; Huang R; Du J; Yang R; An N; Liang A
Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
16. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
17. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
18. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Agnihotri S; Aldape KD; Zadeh G
Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
[TBL] [Abstract][Full Text] [Related]
19. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A
Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
